The magnitude and specificity of immune responses to pathogenic organisms have inspired a search for ways to arm the immune system and aim it at a patient's own metastatic cancer. Knowledge of immune regulation and effector-cell function have grown rapidly in the past decade, and with this knowledge has come incremental gains in the ability to manipulate host immunity and specifically target tumour cells for immune destruction. A convergence of information from the fields of molecular biology and cellular immunology has opened new opportunities for clinical trials using potent immunomodulators and molecularly defined immunogens. The clinical practice of immunotherapy for the treatment of patients with cancer is capitalizing on these advances, and recent efforts in adoptive-cell-transfer (ACT) therapy provide an excellent example of this progress.
A key advance in immunology in the past decade has been the elucidation of the antigenic basis of tumourcell recognition and destruction. The ultimate effector cell that mediates the rejection of solid tumours in preclinical animal models is the CYTOTOXIC T LYMPHOCYTE (CTL). Each CTL expresses a clonotypically unique T-cell-antigen receptor (TCR) that confers specificity for a particular target antigen. The antigens recognized by CTLs consist of peptide fragments, which are bound within the major clefts of MHC-CLASS-I MOLECULES on the cell surface. Cells are exposed to immune-system scrutiny by loading peptide fragments of newly synthesized cellular proteins onto MHC-class-I molecules, which are then transported to the cell surface 1 . As in normal cells, the surfaces of tumour cells contain MHC-peptide antigens that reflect their expressed 'proteome' . T-cell lines can be generated that specifically recognize the HLA-RESTRICTED ANTIGENS that are expressed by tumour cells. These T cells have been used in combination with molecular cloning techniques to identify many genes that encode tumour antigens, and the peptide epitopes derived from them 2 . Tumour antigens have been conceptually grouped into categories based on the genes that encode them. Some tumour antigens, such as an epitope from a mutated β-catenin gene 3 , arise de novo and are unique to individual cancer cells. Other tumour antigens, such as NY-ESO-1(REF. 4 ), are derived from the aberrant expression of non-mutated genes, the products of which are normally expressed only in testes or fetal tissues. Other tumour antigens, such as MART-1 or gp100 (REFS. 5, 6) are derived from non-mutated, cell-lineagespecific proteins. A similar diversity of tumour antigens is recognized by MHC-CLASS-II-restricted CD4 + T CELLS 2 .
The productive engagement of a TCR by cognate MHC/antigen complexes on the target-cell surface triggers the CTL's effector functions and can result in
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Adoptive immunotherapy -the isolation of antigen-specific cells, their ex vivo expansion and activation, and subsequent autologous administration -is a promising approach to inducing antitumour immune responses. The molecular identification of tumour antigens and the ability to monitor the persistence and transport of transferred cells has provided new insights into the mechanisms of tumour immunotherapy. Recent studies have shown the effectiveness of celltransfer therapies for the treatment of patients with selected metastatic cancers. These studies provide a blueprint for the wider application of adoptive-cell-transfer therapy, and emphasize the requirement for in vivo persistence of the cells for therapeutic efficacy.
CYTOTOXIC T LYMPHOCYTES
(CTLs). T lymphocytes that exert a cytolytic function following engagement by their T-cell antigen receptor on target cells. CTLs express the coreceptor CD8 and recognize antigenic peptides (or CTL epitopes) that are presented by HLA-class-I molecules.
the destruction of the target cell. CTLs induce targetcell destruction through the release of inflammatory cytokines (such as tumour-necrosis factor-α and interferon gamma (IFN-γ)), the induction of apoptosisinducing proteins (including FAS ligand (FASL) and TNF-related apoptosis-inducing ligand (TRAIL)) and cytotoxic degranulation, which leads to perforinmediated lysis 7, 8 . However, the existence of tumourreactive CD8 + T CELLS in the peripheral circulation of a patient or an experimental animal is not sufficient to cause the rejection of an established tumour. Clinical trials using peptide antigens for vaccination succeeded in routinely generating tumour-reactive CTLs in patients 9, 10 , but vaccination alone only sporadically induced tumour regression in patients with metastatic disease. Even in transgenic mice, which were engineered to enable every T cell to express a tumour-reactive TCR, tumours still grew progressively 11, 12 . The lack of inflammatory rejection of tumours by immunized patients and TCR transgenic mice is not well understood at the cellular and molecular level. Many mechanisms could account for the failure of antigen-specific CD8 + T cells to eliminate antigenexpressing tumour cells in vivo (FIG. 1) . For instance, the tumour-antigen-specific T cells themselves could be functionally deficient, rendered ANERGIC, or unable to fully differentiate in the tumour environment 13 . The tumour environment could lack a 'danger signal' or other innate immune stimulation, preventing a general inflammatory reaction from evolving 14 . Alternatively, active immune regulatory mechanisms such as CD4 + CD25 + T cells might impede any endogenous immune reaction to cancer cells 15, 16 . Whatever the mechanism, without an inflammatory immune response, the CD8 + T cells of the adaptive immune system are rendered ineffective. As a tumour
Summary
• Adoptive-cell-transfer (ACT) therapy for patients with cancer relies on the ex vivo generation of highly active, tumourspecific lymphocytes, and their administration in large numbers to the autologous host.
• Preclinical models have identified characteristics of lymphocyte cultures that are required for successful ACT therapy. The most important characteristic is the presence of high affinity, tumour-antigen-specific CD8 + T cells. There is generally a direct correlation between treatment efficacy and the number of transferred, tumour-specific cells.
• Preclinical models have also identified ways to manipulate the host immune environment that increase ACT therapeutic efficacy. These include immunosuppression before cell administration and concurrent interleukin 2 administration with the transferred T cells.
• ACT therapy directed at viral antigens has been effective for elimination of Epstein-Barr virus (EBV)-induced posttransplant lymphoproliferative disease. EBV-specific lymphocyte cultures suitable for ACT therapy were generated by repetitive in vitro stimulation using EBV-transformed lymphoblastoid lines.
• Lymphocyte cultures that were selected for reactivity against melanoma antigens, including melanocyte-differentiation antigens, mediated cancer regression in some patients with metastatic melanoma. Melanoma-reactive cultures that were suitable for ACT therapy were generated from tumour-infiltrating lymphocytes that were rapidly expanded with anti-CD3 antibody.
• The generation of tumour-antigen-specific lymphocyte cultures is evolving rapidly, spurred on by the identification of tumour antigens and the T-cell receptors that recognize them.
• Further improvements to ACT therapy will depend on a deeper understanding of basic immunological processes, including the role of CD4 + T cells in the antitumour inflammatory response, the ability of lymphocytes to persist in vivo and travel to tumours, and the mechanisms of ACT augmentation by previous host immunosuppression. effector cells and generating a host environment that is conducive to the function of the transferred cells. These components of ACT therapy have been shown to generate an inflammatory response that is capable of destroying growing tumours. In practice, this strategy has led to substantial tumour regressions in patients with melanoma or lymphoma 18, 19 , and promises to provide treatment options for other refractory-tumour types.
ACT -preclinical studies
Our understanding of tumour immunology has been greatly influenced by ACT studies in animal models. These ACT studies provided the earliest evidence that the immune system could sustain a therapeutic effect against established tumours. Early ACT studies involved splenocytes from immunized mice that were used to treat transplanted SYNGENEIC TUMOURS -more recently these studies have been refined, using TCR-transgenic mouse models. The early studies concentrated on defining the characteristics of the transferred T cell that influenced treatment effectiveness. CD8 + T cells were found to be absolutely required for antitumour effects in many models 20, 21 , and CD4 + T cells were also required for effective treatment of some tumours [22] [23] [24] . In addition, the number of cells transferred was directly correlated with treatment efficacy. Adoptively transferred CD8 + T cells could eliminate only tumour cells that expressed their cognate antigen; recently, a correlation between the antigen avidity of the transferred T cells and efficacy in ACT therapy has been shown 25 . Some functional requirements of the cells for effective ACT were elucidated in animal models, including a correlation between IFN-γ production by T-cell cultures and therapeutic efficacy 26, 27 . The definition of cellular characteristics that are required for therapeutic efficacy in mouse models has led to the examination of similar cellular traits in clinical trials.
Characterization of the transferred T cells has been complemented by analysis of systemic treatments that could improve ACT therapy in mouse models. For example, administration of T-cell growth factors, such as interleukin-2 (IL-2), has greatly improved the persistence and effectiveness of transferred cells [28] [29] [30] [31] . Vaccination with tumour antigens after cell transfer can also increase the persistence of the antigen-specific T cells and improve their effectiveness in mouse tumour-therapy models 32, 33 . This provides a rationale for pursuing vaccination strategies along with ACT therapy in the clinic. Similarly, previous immune suppression markedly improved the efficacy of transferred cells in several mouse models of tumour therapy [34] [35] [36] [37] , and this strategy has also been tested clinically 18 . The relative contributions of these or other mechanisms of host immune manipulation to ACT therapy remain to be fully elucidated in both murine and human systems.
ACT therapy for patients
Preclinical studies have clearly shown the potential for ACT therapy, but a direct translation of the preclinical findings to the clinical treatment of cancer has been hampered as tumour-antigen-specific effector cells are difficult to isolate. grows and metastasizes, additional systemic immunosuppression could develop, and antigen-escape variants of the tumour could arise 17 . This bleak picture of tumour immune evasion has engendered many strategies for immunotherapeutic intervention. ACT therapy is, however, one of the most promising immunotherapy approaches. Several strategies are simultaneously used to allow ACT to overcome tumour-escape mechanisms and enable a successful immune attack against metastatic disease (BOX 1) . With this approach, an investigator first selects effector T cells with optimal characteristics, such as highly avid tumour antigen specificity. The selected lymphocytes are then expanded and activated ex vivo, circumventing in vivo host immune-regulatory mechanisms and potentially suppressive tumour influences. Finally, the patient receives systemic immunosuppressive chemotherapy before ACT, avoiding any toxic effects to the relevant HLA-RESTRICTED ANTIGENS T-cell receptors recognize antigen peptides on the surface of antigen-presenting cells in the context of an HLA molecule. Each HLA allele can bind only a fraction of the potential peptide pool, and this 'restricts' the peptide repertoire. So, the HLArestricted antigenic peptides provide a unique immunological 'signature' that allows immune discrimination of tumour cells, but not normal cells. therapy in patients with metastatic renal-cell carcinoma or melanoma compared with IL-2 therapy alone 48 . Overall, the low response rates reported in these clinical studies, together with data from many animal treatment models, indicate that tumour-antigen-specific lymphocytes are crucial for successful ACT therapy in patients with solid malignancies.
Generating antigen-specific lymphocytes. Several ideas for improving the generation and selection of antigen specific lymphocyte cultures for ACT therapy have been tested clinically. One approach involved vaccinating patients with their autologous tumour cells, harvesting the tumour-vaccine-draining lymph node, and stimulating the recovered lymphocytes for ACT in vitro [49] [50] [51] [52] . Some tumour specificity in the resulting lymphocyte cultures was shown in vitro, and these studies have led to improved methods for activating and culturing lymphocytes to clinically relevant numbers. However, the limited clinical benefit that is seen in most of these clinical trials emphasizes the need for increased specificity of tumourantigen-reactive cells for successful ACT therapy. Additional methods for expanding tumour-antigenspecific lymphocytes from the peripheral blood of immunized patients need to be explored.
The molecular identification of tumour antigens has enabled the investigation of new approaches to generate tumour-specific cultures for ACT. One approach involves the use of dendritic cells that have been pulsed with peptide epitopes from melanoma antigens to stimulate PBLs isolated from patients with melanoma. This approach is similar to that used to generate EBV-specific cultures. In a pilot trial with eight patients, ACT with these cells was found to be safe and well tolerated, modest T-cell persistence was observed, and one objective partial response to treatment was reported 53 . Although this approach is promising, it has been logistically difficult to generate sufficient numbers of dendritic cells to drive large, clinical-scale expansions of lymphocyte cultures. Some investigators have suggested the replacement of dendritic cells with artificial antigen-presenting cells [54] [55] [56] [57] for T-cell expansion, and this approach might hold promise for future clinical studies.
The ultimate example of antigen specificity is embodied in the application of cloned T cells to ACT therapy. The adoptive transfer of T-cell clones was effective in preventing complications from cytomegalovirus (CMV) infection in some bone-marrow-transplant recipients 58 . CMV infection, like EBV reactivation, constitutes an important medical problem for immunosuppressed transplant patients.CMV-specific lymphocyte cultures were generated from the PBLs of bone-marrow donors through in vitro stimulation with CMV-infected fibroblasts. Individual virus-specific clones were then isolated and expanded in vitro and transferred to the marrow recipient for CMV prophylaxis. These CMV-specific CD8 + T-cell clones were shown to be successful in preventing acute infections in the post-transplant period. Interestingly, transferred clones did not persist in all patients, and the endogenous reconstitution of antiviral CD4 + immunity was correlated with CD8 + T-cell persistence. , and the treatment of patients with EBVrelated lymphoma using viral-antigen-specific T cells has become a paradigm for ACT therapy.
The constitutive production of viral antigens by EBVinduced tumours makes them highly susceptible to immune attack. In patients who received bone-marrow transplants, infusions of small numbers of unselected peripheral blood lymphocytes (PBLs) from the bonemarrow donor could mediate antiviral and anti-lymphoma effects 41 . However, donor lymphocyte infusions could also initiate or exacerbate GRAFT-VERSUS-HOST DISEASE, and more specific cellular therapies were sought. Lymphocyte cultures highly enriched for EBV-antigenspecific T cells were generated by repetitive in vitro stimulation of PBLs with EBV-B lymphoblastic cell lines 19 . These EBV-B cells efficiently presented viral antigens, and provided other CO-STIMULATION necessary to activate and expand T cells in vitro. Starting with PBLs, several rounds of EBV-B stimulation generated cultured T cells that were ideal for ACT therapy. These cultured cells were highly tumour reactive, phenotypically heterogeneous (containing both CD8 + and CD4 + T cells) and maintained their proliferative potential. Most importantly, these cultures were effective in ACT therapy for inhibiting EBV-induced lymphoproliferation. This method of repetitive in vitro restimulation to increase the fraction of tumour-specific cells generates effector lymphocyte populations, and these could be used in ACT therapy of other tumour types.
Non-viral-antigen-expressing tumours. For patients with tumours that do not express viral antigens, the development of ACT therapies has had limited success because the generation of tumour-antigen-specific cells has been problematic. Many clinical trials were undertaken using non-specific, activated lymphocytes to treat patients with metastatic cancer. For instance, the generation and transfer of LYMPHOKINE-ACTIVATED KILLER CELLS (LAKs) has been extensively investigated in preclinical and clinical models [42] [43] [44] . Others have tried non-specific PBLs that were activated in vitro with anti-CD3 antibodies [45] [46] [47] . Some of these trials with non-specific cells resulted in sporadic or inconsistent tumour responses. In other trials, the concurrent use of IL-2 or chemotherapy with the transfer of non-specific cells confounded the interpretation of response rates. A prospective randomized trial did not show a statistically significant benefit of LAK ACT
MHC-CLASS-II MOLECULES
Peptide receptors, similar to class-I molecules in structure and function, but expressed by a small set of professional antigen-presenting immune cells. They mainly present peptides from extracellular proteins to T-helper cells. 
SYNGENEIC TUMOURS
Tumours derived from mice with an identical genetic background; specifically, the same inbred line.
GRAFT-VERSUS-HOST DISEASE
A toxic reaction that is mediated by donor-derived T lymphocytes within the graft towards the recipient's organs. The attack is usually directed toward the skin, gut, liver and haematopoietic cells. 
R E V I E W S
CD3
A multimeric component of the T-cell-receptor signalling apparatus. Direct activation of T cells by antibody cross-linking of CD3 complexes on the cell surface bypasses the requirement for T-cell receptor engagement of HLA-restricted antigens. could account for the lack of clonal persistence and therapeutic efficacy in these ACT trials. These include a requirement for antigen-specific CD4 + T cells 64 ; proliferative exhaustion or terminal differentiation of clones during expansion 62 ; aberrant transport or reduced survival of ineffective cells 65 ; or selection by clones of antigen-loss tumour variants in vivo 61 . A highly effective method for generating tumourspecific lymphocyte cultures from patients with melanoma was indicated by preclinical studies in mice. Tumour-infiltrating lymphocytes (TILs) from transplantable mouse sarcomas cultured in high levels of IL-2 showed specific lytic activity towards the cognate tumour cells in vitro. These lymphocytes also mediated tumour regression when transferred into tumourbearing mice 31 . Some human tumours, including melanoma [66] [67] [68] [69] , renal-cell carcinoma 70 and glioma 71 , could also generate TILs that were suitable for use in ACT therapy. Melanoma lesions seem particularly suited to this approach, as patients with melanoma can be naturally immunized against antigens expressed by their own tumours 72 , and melanoma lesions seem to be a repository for tumour-reactive T cells. The use of TILs In contrast to the clinical efficacy that is seen in trials with anti-CMV clones for viral prophylaxis, cloned melanoma-reactive T cells were ineffective at mediating marked tumour regression. Objective tumour regressions (defined as greater than a 50% decrease in the sum of the products of perpendicular diameters of all lesions with no growth in any lesion) were not seen in immunocompetent or immunosuppressed patients when clones were transferred with or without IL-2 administration [59] [60] [61] . In our studies, transferred tumour-reactive clones disappeared rapidly from the circulation of patients, whether monitored by sensitive fluorescence-cytometry or polymerase-chain-reaction methods (BOX 2) . In a study by Yee et al., extended administration of low-dose IL-2 enhanced the clonallymphocyte survival, but was not sufficient to induce objective tumour responses. Clones that reacted against HIV antigens also failed to persist in vivo, when tested for their ability to treat patients with HIV infection 62, 63 . An important conclusion from these studies is that highly avid recognition of tumour antigens by the transferred lymphocyte culture is necessary, but is not sufficient, for treatment efficacy. Several explanations . Cells were infused on the first day following chemotherapy by intravenous administration over 30-60 minutes, and patients received high-dose IL-2 therapy consisting of 720,000 IU/kg by bolus intravenous infusion every 8 hours to tolerance. Some patients with mixed or minor responses received an additional course of ACT therapy. Antigen specificity was determined by cytokine-release assays. Autologous, recognition of autologous tumour cells mediated by undetermined antigens; gp100, recognition of the HLA-A2-restricted gp100 peptide; MART-1, recognition of the HLA-A2-restricted 'melanoma antigen recognized by T cells' (MART)-1 peptide; NR, no objective response; NR/m, partial response of some lesions with progression at other sites; PR, partial response (greater than 50% reduction in the sum of the cross-sectional area of all lesions with no progressive lesion and no new lesion).
Box 2 | Assessing T-cell persistence after transfer
Monitoring the persistence and localization of adoptively transferred T cells is crucial for evaluating and improving adoptive-cell-transfer (ACT) therapies
ACT therapy 37 . More recently, Sakaguchi et al. showed that the elimination of CD4 + CD25 + regulatory T cells can greatly improve adoptive immunotherapy 16 . Alternatively, lymphocyte depletion might create 'space' in the lymphocyte compartment 84 , and provide homeostatic lymphocyte-survival and proliferative signals such as IL-7 (REF. 85 ). Others have suggested that the success of ACT therapy for the treatment of EBV-related lymphoma and for prophylaxis of CMV infection is due, in part, to the immunosuppressed status of the patients receiving treatment. These examples constitute a strong rationale for the use of clinical trials to investigate the combination of lymphodepletion and ACT therapy.
We recently investigated the addition of a nonmyeloablative, but lymphodepleting conditioning regimen to ACT therapy for the treatment of patients with metastatic melanoma 18 
. Patients had received a lymphodepleting chemotherapy regimen consisting of cyclophosphamide and fludarabine before lymphocyte administration. This conditioning regimen caused transient myelosuppression and the virtual elimination of circulating lymphocytes for about a week. Patients typically recovered endogenous marrow function and reconstituted their lymphocyte compartment to normal levels within 2-3 weeks of chemotherapy 60 . Some patients experienced delayed recovery of CD4 + T-cell counts and extended immunosuppression. Highly selected, highly expanded, tumour-reactive TIL cultures were administered to the lymphodepleted patients, who also received IL-2 therapy. This treatment resulted in the substantial regression of metastatic melanoma deposits in some treated patients.
A summary of this treatment approach for the first 13 HLA-A2 patients treated is shown in TABLE 1. All 13 patients involved in the study had progressive metastatic melanoma before ACT therapy, despite having undergone several previous treatments that included surgery, experimental immunotherapy, high-dose IL-2 therapy and (for many) aggressive chemotherapy. Six patients showed a greater than 50% reduction at all tumour sites, and four others showed mixed responses with substantial shrinkage of some lesions, but growth at other sites. Significant levels of tumour regression occurred in metastatic deposits in the lungs, liver, cutaneous and subcutaneous tissues, and lymph nodes (FIG. 2) . The tumour regressions observed in some patients responding to ACT therapy were accompanied by striking immunological findings. TIL transfer following nonmyeloablative conditioning led to the in vivo proliferation of the transferred cells in some patients. These cells repopulated the patients' immune systems and persisted at high levels in the peripheral blood. Two patients experienced stable engraftment of self-antigen-reactive T-cell clones, which made up over 70% of circulating CD8 + T cells, for many months after TIL administration. This engraftment and long-term persistence of tumour-specific lymphocytes in patients with metastatic cancer represents the achievement of one of the main goals of the immunotherapy of patients with cancer.
in the treatment of patients with cancer histologies other than melanoma has not been effective, probably because TILs from other tumour types rarely produce CD8 + T cells that recognize the autologous tumour [73] [74] [75] [76] [77] . TIL cultures generated from melanoma lesions were often highly lytic -especially when tested against their autologous tumour 78-80 -and most TILs contained both CD8 + and CD4 + T cells. Recent refinement in methods for growing TIL cultures suitable for ACT therapy resulted in the generation of autologous tumourreactive lymphocytes from 78% of patients 81 . In clinical trials at our institution, 34% of immunocompetent patients with melanoma who were treated with bulk TIL administration and high-dose IL-2 therapy achieved objective clinical responses 82 . Most of the responses, however, were transient, and limited persistence of the transferred cells was seen 83 .
ACT therapy following lymphodepletion
Several lines of evidence indicate that the host immune environment can markedly impact the efficacy of ACT therapy. Evidence from preclinical models indicated that host immunosuppression before ACT was highly effective for increasing the impact of the transferred cells. The mechanisms of enhancement of ACT therapy by immune suppression have not been unambiguously determined, but several hypotheses have been investigated. In 1982, North described a CD4 + T-lymphocyte population that suppressed the antitumour effects of cells to the T cells 87, 91, 92 . Clinical trials with these genetically enginereed lymphocytes will soon begin to assess the utility of this approach.
Concurrently, a growing appreciation of lymphocyte characteristics other than antigen specificity that can impact lymphocyte behaviour in vivo is influencing the practice of ACT therapy. For instance, the discovery that the maturation state of CD8 + T lymphocytes determines their in vivo transport and persistence during an immune response 93, 94 indicates new avenues for manipulating T-cell behaviour. These might include the alteration of in vitro T-cell cultures to maintain a central memory phenotype -for instance by altering the cytokine milieu during T-cell growthor genetically engineering lymphocytes to constitutively express their own growth factors that would enhance survival after cytokine withdrawal in vivo 95 . A more detailed understanding of these and other factors influencing CD8
+ T-cell persistence in vivo could improve ACT therapy.
Rapid progress in understanding the role of the host immune environment on tumour therapy is also likely to impact on the practice of cell-based therapies. For instance, the dual role of CD4 + T cells in tumour immunity has important clinical implications. The recent reports describing a requirement of CD4 + T cells for persistence of CD8 + T cells after an immune response 96, 97 underscores a potential role of CD4 + T cells in TIL cultures for ACT therapy. By contrast, the demonstration that CD4 + CD25 + T cells suppress autoimmunity and might be potent inhibitors of antitumour effects in mice indicates a rationale for additional investigation of lymphodepleting conditioning for ACT therapy. These opposing effects of CD4 + T cells highlight the need for additional investigation of CD4 + T-cell-mediated antitumour immunity. A better understanding of the homeostatic regulation of T-cell number and activation, and the role of concurrent vaccination after Tcell transfer has similar potential for improving ACT therapy . Each of these manipulations of the host immune environment is being translated for clinical investigation in ACT clinical protocols. These technologies can be combined with emerging strategies and new biological therapeutics for systemic immune stimulation to improve and enhance the scope and efficacy of ACT therapy. Interestingly, five of the patients also experienced the autoimmune destruction of normal melanocytes.Vitiligo (skin depigmentation) was seen in four patients, and has been previously described in melanoma patients receiving an immune-based therapy 86, 87 . Autoimmune inflammation of the eye, uveitis, was effectively treated with local steroids in one additional patient treated in this trial. The concordant onset of melanoma regression and autoimmune melanocyte destruction raises interesting parallels between autoimmunity and tumour therapy. Others have reported a link between these immune phenomena in mouse models and in human patient populations. Successful, antigen-directed immunotherapy of the B16 murine melanoma also led to the onset of normal melanocyte destruction 88, 89 . Furthermore, non-specific suppression of immune regulation through CTLA-4 blockade in patients with melanoma led to tumour regression in some patients 90 that was also associated with autoimmune toxicity. These results indicate that autoimmunity and tumour rejection share some underlying mechanisms or require immune responses of a similar magnitude. These results also indicate that ACT therapy is capable of unleashing a potent tissue-destructive capacity, and the challenge for the future is to learn to direct these responses to antigens that are unique to tumours or that are expressed only on non-essential normal tissues.
Improving ACT therapy
Recent clinical success with ACT therapy is motivating additional investigation of this treatment modality. Substantial improvements in clinical outcomes for patients can be obtained by improvements in generating T cells for transfer and in manipulating the host immune environment to enhance in vivo antitumour activities. The generation of active, tumour-specific lymphocyte cultures with the characteristics necessary for in vivo effectiveness remains a considerable obstacle to the application of ACT therapy. The molecular characterization of tumour antigens has created the possibility of using these defined tumour antigens to generate tumour-specific lymphocyte cultures for patient treatment by repetitive in vitro stimulations. Another approach involves the genetic engineering of T cells to express a defined antigen specificity. Several investigators have reported that the transfer to PBLs of a gene encoding a tumour-antigen-specific T-cell receptor conferred specific recognition of tumour
